As of 2024-12-15, the Relative Valuation of Neovacs SA (ALNEV.PA) is (2,871.20) EUR. This relative valuation is based on P/E multiples. With the latest stock price at 1.60 EUR, the upside of Neovacs SA based on Relative Valuation is -179549.7%.
The range of the Relative Valuation is (2,564.41) - (3,177.98) EUR.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 13.0x - 16.2x | 14.6x |
| Forward P/E multiples | 13.0x - 16.2x | 14.6x |
| Fair Price | (2,564.41) - (3,177.98) | (2,871.20) |
| Upside | -160375.6% - -198723.8% | -179549.7% |
| Date | P/E |
| 2024-11-20 | -0.00 |
| 2024-11-19 | -0.00 |
| 2024-11-18 | -0.00 |
| 2024-11-15 | -0.00 |
| 2024-11-14 | -0.00 |
| 2024-11-13 | -0.00 |
| 2024-11-12 | -0.00 |
| 2024-11-11 | -0.00 |
| 2024-11-08 | -0.00 |
| 2024-11-07 | -0.00 |
| 2024-11-06 | -0.00 |
| 2024-11-05 | -0.00 |
| 2024-11-04 | -0.00 |
| 2024-11-01 | -0.00 |
| 2024-10-31 | -0.00 |
| 2024-10-30 | -0.00 |
| 2024-10-29 | -0.00 |
| 2024-10-28 | -0.00 |
| 2024-10-25 | -0.00 |
| 2024-10-24 | -0.00 |
| 2024-10-23 | -0.00 |
| 2024-10-22 | -0.00 |
| 2024-10-21 | -0.00 |
| 2024-10-18 | -0.00 |
| 2024-10-17 | -0.00 |
| 2024-10-16 | -0.00 |
| 2024-10-15 | -0.00 |
| 2024-10-14 | -0.00 |
| 2024-10-11 | -0.00 |
| 2024-10-10 | -0.00 |
| 2024-10-09 | -0.00 |
| 2024-10-08 | -0.00 |
| 2024-10-07 | -0.00 |
| 2024-10-04 | -0.00 |
| 2024-10-03 | -0.00 |
| 2024-10-02 | -0.00 |
| 2024-10-01 | -0.00 |
| 2024-09-30 | -0.00 |
| 2024-09-27 | -0.00 |
| 2024-09-26 | -0.00 |
| 2024-09-25 | -0.00 |
| 2024-09-24 | -0.00 |
| 2024-09-23 | -0.00 |
| 2024-09-20 | -0.00 |
| 2024-09-19 | -0.00 |
| 2024-09-18 | -0.00 |
| 2024-09-17 | -0.00 |
| 2024-09-16 | -0.00 |
| 2024-09-13 | -0.00 |
| 2024-09-12 | -0.00 |